The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura

How I treat refractory thrombotic thrombocytopenic purpura

(2015) Farzana A. Sayani et al.   BLOOD

N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?

(2015) Jake Shortt et al.   TRANSFUSION

ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura

(2013) Jake Shortt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of refractory thrombotic thrombocytopenic purpura withN-acetylcysteine: a case report

(2013) Gloria W. Li et al.   TRANSFUSION

Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura

(2012) John Chapin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis

(2012) Nay M. Tun et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice

(2011) Junmei Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

How I treat patients with thrombotic thrombocytopenic purpura: 2010

(2010) J. N. George   BLOOD

N-acetylcysteine is associated with increased blood loss and blood product utilization during cardiac surgery*

(2009) Duminda N. Wijeysundera et al.   CRITICAL CARE MEDICINE